Released Mar 27, 2026, before the open
10-K filed Mar 27, 2026, 86 days after period end · 0001785530-26-000006
Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$8.38M-$8.38M derivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$9,418,000N/M
Operating Cash Flowderived-$11,024,000N/M
Free Cash Flowderived-$11,024,000N/M
What the release said
The release
Same quarter
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Net Income | -$8.38M | -$20.40M | -$12.00M | -$11.93M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR